KRAS mutation testing in colorectal cancer: Comparison of the results obtained using 3 different methods for the analysis of codons G12 and G13

Diagnostic Molecular Pathology

Volumn 21, Issue 1, 2012, Pages 14-23

  Bihl, Michel P ^a   Hoeller, Sylvia ^a   Andreozzi, Maria Carla ^a   Foerster, Anja ^a   Rufle, Alexander ^a   Tornillo, Luigi ^a   Terracciano, Luigi ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

KRAS; methods; molecular test; mutation

Indexed keywords

ARTICLE; CODON; COLORECTAL CARCINOMA; DIDEOXYSEQUENCING; GENE MUTATION; GENETIC PROCEDURES; INFINITI ANALYZER; ONCOGENE K RAS; PRIORITY JOURNAL; PYROSEQUENCING; RELIABILITY; SENSITIVITY ANALYSIS; TURNAROUND TIME;

ADENOCARCINOMA; BASE SEQUENCE; CODON; COLORECTAL NEOPLASMS; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MOLECULAR SEQUENCE DATA; MUTATION; PROTO-ONCOGENE PROTEINS; RAS PROTEINS;

EID: 84857233013     PISSN: 10529551     EISSN: 15334066     Source Type: Journal    
DOI: 10.1097/PDM.0b013e31822b831a     Document Type: Article

References (11)

1. Saltz LB, Meropol NJ, Loehrer PJ, et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol. 2004;22:1201-1208. (Pubitemid 41079832)
2. Allegra CJ, Jessup JM, Somerfield MR, et al. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol. 2009;27:2091-2096.
3. De Roock W, Piessevaux H, De Schutter J, et al. KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol. 2008;19:508-515. (Pubitemid 351325672)
4. Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med. 2008;359:1757-1765.
5. Plesec TP, Hunt JL. KRAS mutation testing in colorectal cancer. Adv Anat Pathol. 2009;16:196-203.
6. Whitehall V, Tran K, Umapathy A, et al. A multicenter blinded study to evaluate KRAS mutation testing methodologies in the clinical setting. J Mol Diagn. 2009;11:543-552.
7. Poehlmann A, Kuester D, Meyer F, et al. K-ras mutation detection in colorectal cancer using the Pyrosequencing technique. Pathol Res Pract. 2007;203:489-497. (Pubitemid 47065358)
8. Dufort S, Richard MJ, de Fraipont F. Pyrosequencing method to detect KRAS mutation in formalin-fixed and paraffin-embedded tumor tissues. Anal Biochem. 2009;391:166-168.
9. Krypuy M, Newnham GM, Thomas DM, et al. High resolution melting analysis for the rapid and sensitive detection of mutations in clinical samples: KRAS codon 12 and 13 mutations in non-small cell lung cancer. BMC Cancer. 2006;6:295.
10. Kotoula V, Charalambous E, Biesmans B, et al. Targeted KRAS mutation assessment on patient tumor histologic material in real time diagnostics. PLoS One. 2009;4:e7746.
11. Ogino S, Kawasaki T, Brahmandam M, et al. Sensitive sequencing method for KRAS mutation detection by pyrosequencing. J Mol Diagn. 2005;7:413-421. (Pubitemid 41149657)